Marker Therapeutics to Present at the Virtual Raymond James Human Health Innovation Conference
Marker Therapeutics, Inc. (NASDAQ: MRKR) announced that Chief Financial Officer Anthony H. Kim will present at the virtual Raymond James Human Health Innovation Conference on June 21, 2021, at 9:20 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Marker Therapeutics, Inc. (NASDAQ: MRKR) announced that Chief Financial Officer Anthony H. Kim will present at the virtual Raymond James Human Health Innovation Conference on June 21, 2021, at 9:20 a.m. ET. Marker Therapeutics is focused on developing next-generation T cell-based immunotherapies for treating hematological malignancies and solid tumors. The presentation will be available via a live webcast on their website and can be replayed afterward. The company's innovative approach emphasizes non-engineered, tumor-specific T cells, potentially reducing manufacturing costs and toxicities while enhancing patient outcomes.
Details
News Market Reaction – MRKR
The recorded move for MRKR in the trading session of this news was +2.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, June 16, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Financial Officer, Anthony H. Kim, will present at the upcoming virtual Raymond James Human Health Innovation Conference on Monday, June 21, 2021 at 9:20 a.m. ET.
A live webcast of the presentation will be accessible from the Investors section of the company's website at markertherapeutics.com and will be available for replay following the event.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.
To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.
View original content to download multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-to-present-at-the-virtual-raymond-james-human-health-innovation-conference-301314112.html
SOURCE Marker Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.